TY - JOUR
T1 - Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α
T2 - Receptors, functions, and roles in diseases
AU - Akdis, Mübeccel
AU - Aab, Alar
AU - Altunbulakli, Can
AU - Azkur, Kursat
AU - Costa, Rita A.
AU - Crameri, Reto
AU - Duan, Su
AU - Eiwegger, Thomas
AU - Eljaszewicz, Andrzej
AU - Ferstl, Ruth
AU - Frei, Remo
AU - Garbani, Mattia
AU - Globinska, Anna
AU - Hess, Lena
AU - Huitema, Carly
AU - Kubo, Terufumi
AU - Komlosi, Zsolt
AU - Konieczna, Patricia
AU - Kovacs, Nora
AU - Kucuksezer, Umut C.
AU - Meyer, Norbert
AU - Morita, Hideaki
AU - Olzhausen, Judith
AU - O'Mahony, Liam
AU - Pezer, Marija
AU - Prati, Moira
AU - Rebane, Ana
AU - Rhyner, Claudio
AU - Rinaldi, Arturo
AU - Sokolowska, Milena
AU - Stanic, Barbara
AU - Sugita, Kazunari
AU - Treis, Angela
AU - van de Veen, Willem
AU - Wanke, Kerstin
AU - Wawrzyniak, Marcin
AU - Wawrzyniak, Paulina
AU - Wirz, Oliver F.
AU - Zakzuk, Josefina Sierra
AU - Akdis, Cezmi A.
N1 - Funding Information:
Supported by the Swiss National Science Foundation no. 310030_156823 and 320030-159870 and the Christine Kühne-Center for Allergy Research and Education (CK-CARE).
Funding Information:
Disclosure of potential conflict of interest: M. Akdis is employed by the Swiss Institute of Allergy and Asthma Research, University of Zurich and has received grants from PREDICTA: European Commission's Seventh Framework programme no. 260895 and the Swiss National Science Foundation. R. Crameri is employed by the Swiss Institute of Allergy and Asthma Research and has received grants from the Swiss National Science Foundation. L. O'Mahony has consultant arrangements with Alimentary Health Ltd and has received grants from GlaxoSmithKline. M. Pezer has received grants from the European Academy of Allergy and Clinical Immunology, the Global Allergy and Asthma European Network (GA 2 LEN), and the International Society for Applied Biological Sciences. C. Rhyner is employed by the Swiss Institute of Allergy and Asthma Research and has received a grant from the Commission for Technology and Innovation. B. Stanic is employed by AO Research Institute Davos. C. Akdis has consultant arrangements with Actellion, Aventis, Stallergenes, Allergopharma, and Circacia; is employed by the Swiss Institute of Allergy and Asthma Research, University of Zurich; and has received grants from Novartis, PREDICTA: European Commission's Seventh Framework programme no. 260895, Swiss National Science Foundation, MeDALL: European Commission's Seventh Framework Programme no. 261357, and Christine Kühne-Center for Allergy Research and Education. The rest of the authors declare that they have no relevant conflicts of interest.
Publisher Copyright:
© 2016 American Academy of Allergy, Asthma & Immunology
PY - 2016/10/1
Y1 - 2016/10/1
N2 - There have been extensive developments on cellular and molecular mechanisms of immune regulation in allergy, asthma, autoimmune diseases, tumor development, organ transplantation, and chronic infections during the last few years. Better understanding the functions, reciprocal regulation, and counterbalance of subsets of immune and inflammatory cells that interact through interleukins, interferons, TNF-α, and TGF-β offer opportunities for immune interventions and novel treatment modalities in the era of development of biological immune response modifiers particularly targeting these molecules or their receptors. More than 60 cytokines have been designated as interleukins since the initial discoveries of monocyte and lymphocyte interleukins (called IL-1 and IL-2, respectively). Studies of transgenic or gene-deficient mice with altered expression of these cytokines or their receptors and analyses of mutations and polymorphisms in human genes that encode these products have provided essential information about their functions. Here we review recent developments on IL-1 to IL-38, TNF-α, TGF-β, and interferons. We highlight recent advances during the last few years in this area and extensively discuss their cellular sources, targets, receptors, signaling pathways, and roles in immune regulation in patients with allergy and asthma and other inflammatory diseases.
AB - There have been extensive developments on cellular and molecular mechanisms of immune regulation in allergy, asthma, autoimmune diseases, tumor development, organ transplantation, and chronic infections during the last few years. Better understanding the functions, reciprocal regulation, and counterbalance of subsets of immune and inflammatory cells that interact through interleukins, interferons, TNF-α, and TGF-β offer opportunities for immune interventions and novel treatment modalities in the era of development of biological immune response modifiers particularly targeting these molecules or their receptors. More than 60 cytokines have been designated as interleukins since the initial discoveries of monocyte and lymphocyte interleukins (called IL-1 and IL-2, respectively). Studies of transgenic or gene-deficient mice with altered expression of these cytokines or their receptors and analyses of mutations and polymorphisms in human genes that encode these products have provided essential information about their functions. Here we review recent developments on IL-1 to IL-38, TNF-α, TGF-β, and interferons. We highlight recent advances during the last few years in this area and extensively discuss their cellular sources, targets, receptors, signaling pathways, and roles in immune regulation in patients with allergy and asthma and other inflammatory diseases.
KW - adaptive immune response
KW - allergy and asthma
KW - B cells
KW - Cytokines
KW - dendritic cells
KW - humoral immune response
KW - innate immune response
KW - interleukins
KW - T cells
UR - http://www.scopus.com/inward/record.url?scp=84992195167&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2016.06.033
DO - 10.1016/j.jaci.2016.06.033
M3 - Review article
C2 - 27577879
AN - SCOPUS:84992195167
SN - 0091-6749
VL - 138
SP - 984
EP - 1010
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 4
ER -